LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 21 of 166
Next
>>
>
501 to 525 of 4140 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Timepoint	Timepoint Unit	Mean Total Cell Count Before Treatment	Mean Total Cell Count After Treatment	Mean Total Control Cell Count	Mean Relative Cell Count	Mean Normalized Growth Rate Inhibition Value
BT-20	GSK1904529A	0.12	uM	LJP6	72	hr	1334	3753	3925	0.9565	0.9435
BT-20	GSK1904529A	0.37	uM	LJP6	72	hr	1334	3680	3925	0.9377	0.9189
BT-20	Linsitinib	0.04	uM	LJP5	72	hr	1334	3462	4033	0.8589	0.8180
BT-20	Linsitinib	0.12	uM	LJP5	72	hr	1334	3722	4033	0.9226	0.9010
BT-20	Linsitinib	1.11	uM	LJP5	72	hr	1334	3950	4033	0.9796	0.9742
BT-20	Linsitinib	3.33	uM	LJP5	72	hr	1334	3836	4033	0.9519	0.9395
BT-20	Ruxolitinib	0.12	uM	LJP5	72	hr	1334	3911	4033	0.9699	0.9621
BT-20	Ruxolitinib	0.37	uM	LJP5	72	hr	1334	4023	4033	0.9979	0.9978
BT-20	Ruxolitinib	3.33	uM	LJP5	72	hr	1334	3901	4033	0.9671	0.9581
BT-20	Ruxolitinib	10	uM	LJP5	72	hr	1334	3058	4033	0.7587	0.6823
BT-20	Seliciclib	0.04	uM	LJP5	72	hr	1334	4094	4033	1.0156	1.0199
BT-20	Seliciclib	0.12	uM	LJP5	72	hr	1334	4007	4033	0.9941	0.9928
BT-20	Seliciclib	1.11	uM	LJP5	72	hr	1334	3827	4033	0.9489	0.9352
BT-20	Seliciclib	3.33	uM	LJP5	72	hr	1334	3442	4033	0.8529	0.8091
BT-20	AT-7519	0.12	uM	LJP6	72	hr	1334	3834	3925	0.9770	0.9701
BT-20	AT-7519	0.37	uM	LJP6	72	hr	1334	3020	3925	0.7695	0.6901
BT-20	AT-7519	3.33	uM	LJP6	72	hr	1334	350	3925	0.0894	-0.5784
BT-20	AT-7519	10	uM	LJP6	72	hr	1334	285	3925	0.0728	-0.6302
BT-20	AZD7762	1.11	uM	LJP6	72	hr	1334	2258	3925	0.5752	0.4018
BT-20	AZD7762	3.33	uM	LJP6	72	hr	1334	1438	3925	0.3665	0.0491
BT-20	AZD8055	0.04	uM	LJP6	72	hr	1334	2367	3925	0.6035	0.4440
BT-20	AZD8055	0.12	uM	LJP6	72	hr	1334	1948	3925	0.4964	0.2749
BT-20	AZD8055	3.33	uM	LJP6	72	hr	1334	1391	3925	0.3546	0.0263
BT-20	Fedratinib	0.37	uM	LJP5	72	hr	1334	3888	4033	0.9643	0.9550
BT-20	Fedratinib	0.12	uM	LJP5	72	hr	1334	3935	4033	0.9753	0.9679

|<
<<
Previous
Page 21 of 166
Next
>>
>
501 to 525 of 4140 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 12 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 2. - Dataset (ID:20249)